Location, location, location: Sub-cellular specific targeting of JNK as a novel therapy in breast cancer.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1148099

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The ‘triple negative’ breast cancer subtype is the most aggressive form of breast cancer, and unlike other subtypes, there are no drugs to specifically this subtype. While many potential drug targets have been identified, they cannot be utilised clinically because of other beneficial roles within the body. We are now deploying our innovative experimental platforms to specifically target the tumour promoting functions of a protein known as ‘JNK’, whilst retaining its beneficial functions.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $633,755.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Signal Transduction

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biosensor | imaging | mechanotransduction | protein interactions | signalling pathways

Related Links